Announced details
PDX model, monotherapy: 28% inhibition of tumor growth
PDX model, in combination with cetuximab: 53% inhibition of tumor growth
CDX model: near-complete tumor regression
Akatsuki Therapeutics is a development partner. Helios is conducting or promoting joint research with the National Cancer Center, Hyogo Medical University, Hiroshima University Graduate School and Kyushu University.
Akatsuki Therapeutics is headquartered at 8-1 Kakuda-cho, Kita-ku, Osaka, Osaka Prefecture, and its Representative Director and President is Saito Hikaru (齊藤光). It is a portfolio company of Saisei Ventures LLC, which develops cellular immunotherapies for cancer and serious diseases. For the other counterparties, no information is provided beyond their status as collaborative research partners.
DOI：10.1007/s00262-026-04370-7
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Cancer Immunology, Immunotherapy
| Item | Details |
|---|---|
| Names of Products / Services Covered | eNK® cells (development code: AKT-01/HLCN061) |
| Counterparty | Akatsuki Therapeutics, National Cancer Center, Hyogo Medical University, Hiroshima University Graduate School, National University Corporation Kyushu University |
| Counterparty overview | Akatsuki Therapeutics is headquartered at 8-1 Kakuda-cho, Kita-ku, Osaka, Osaka Prefecture, and its Representative Director and President is Saito Hikaru (齊藤光). It is a portfolio company of Saisei Ventures LLC, which develops cellular immunotherapies for cancer and serious diseases. For the other counterparties, no information is provided beyond their status as collaborative research partners. |
| Relationship with the Company | Akatsuki Therapeutics is a development partner. Helios is conducting or promoting joint research with the National Cancer Center, Hyogo Medical University, Hiroshima University Graduate School and Kyushu University. |
| Applicable area | Difficult-to-treat solid tumors, including lung cancer, Mesothelioma, Hepatocellular carcinoma, Brain tumors |
| Registration number and expiry date | DOI：10.1007/s00262-026-04370-7 |
| Quantitative Effects | PDX model, monotherapy: 28% inhibition of tumor growth, PDX model, in combination with cetuximab: 53% inhibition of tumor growth, CDX model: near-complete tumor regression |
| Source | Cancer Immunology, Immunotherapy |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research findings on the antitumor effects of eNK® cells against lung cancer were published in a peer-reviewed journal.